Comparing how significantly the pharmacological treatment of genitourinary cancer in a non-curative setting affects endpoints of survival or response

World Journal of Urology

Volumn 31, Issue 1, 2013, Pages 117-125

  Yates, David R ^a   Rouprêt, Morgan ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Bladder cancer; Chemotherapy; Kidney cancer; Oncology; Palliative treatment; Prostate cancer

Indexed keywords

EID: 84873172291     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-011-0798-5     Document Type: Review

References (60)

1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Sullivan R, Peppercorn J, Sikora K et al (2011) Delivering affordable cancer care in high-income countries. Lancet Oncol 12: 933-980.
3. Chang SS (2007) Treatment options for hormone-refractory prostate cancer. Rev Urol 9(Suppl 2): S13-S18.
4. Lu-Yao G, Moore DF, Oleynick JU et al (2007) Population based study of hormonal therapy and survival in men with metastatic prostate cancer. J Urol 177: 535-539.
5. Seidenfeld J, Samson DJ, Hasselblad V et al (2000) Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 132: 566-577.
6. Byar DP (1973) Proceeding: the veterans administration cooperative urological research group studies of cancer of the prostate. Cancer 32: 1126-1130.
7. Smith DC, Redman BG, Flaherty LE et al (1998) A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 52: 257-260.
8. Hedlund PO, Henriksson P (2000) Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The scandinavian prostatic cancer group (SPCG)-5 trial study. Urology 55: 328-333.
9. Klotz L, McNeill I, Fleshner N (1999) A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol 161: 169-172.
10. Klein D (1972) Treatment with estramustine phosphate in advanced prostatic cancer. Wien Med Wochenschr 122: 458-460.
11. Hudes G (1997) Estramustine-based chemotherapy. Semin Urol Oncol 15: 13-19.
12. Fizazi K, Le Maitre A, Hudes G et al (2007) Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 8: 994-1000.
13. Tannock I, Gospodarowicz M, Meakin W et al (1989) Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7: 590-597.
14. Venkitaraman R, Thomas K, Huddart RA et al (2008) Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. BJU Int 101: 440-443.
15. Nishimura K, Nonomura N, Yasunaga Y et al (2000) Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89: 2570-2576.
16. Sartor O, Weinberger M, Moore A et al (1998) Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology 52: 252-256.
17. Trachtenberg J, Halpern N, Pont A (1983) Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. J Urol 130: 152-153.
18. Mahler C, Verhelst J, Denis L (1993) Ketoconazole and liarozole in the treatment of advanced prostatic cancer. Cancer 71: 1068-1073.
19. Nakabayashi M, Xie W, Regan MM et al (2006) Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer 107: 975-981.
20. Small EJ, Halabi S, Dawson NA et al (2004) Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22: 1025-1033.
21. Nakabayashi M, Oh WK, Jacobus S et al (2010) Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. BJU Int 105: 1392-1396.
22. Scholz M, Jennrich R, Strum S et al (2005) Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone. J Urol 173: 1947-1952.
23. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512.
24. Berthold DR, Pond GR, Soban F et al (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26: 242-245.
25. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520.
26. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376: 1147-1154.
27. Scher HI, Beer TM, Higano CS et al (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375: 1437-1446.
28. Attard G, Reid AH, Yap TA et al (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26: 4563-4571.
29. Danila DC, Morris MJ, de Bono JS et al (2010) Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 28: 1496-1501.
30. Reid AH, Attard G, Danila DC et al (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28: 1489-1495.
31. Attard G, Reid AH, A'Hern R et al (2009) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27: 3742-3748.
32. Hussain SA, James ND (2003) The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 4: 489-497.
33. von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18: 3068-3077.
34. Loehrer PJ Sr, Einhorn LH, Elson PJ et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10: 1066-1073.
35. Saxman SB, Propert KJ, Einhorn LH et al (1997) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15: 2564-2569.
36. Von der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23: 4602-4608.
37. Sternberg CN, de Mulder P, Schornagel JH et al (2006) Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42: 50-54.
38. Stenzl A, Cowan NC, De Santis M et al (2009) The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 55: 815-825.
39. Dogliotti L, Carteni G, Siena S et al (2007) Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 52: 134-141.
40. De Santis M, Bellmunt J, Mead G et al (2009) Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II-results of EORTC study 30986. J Clin Oncol 27: 5634-5639.
41. Culine S, Theodore C, De Santis M et al (2006) A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 94: 1395-1401.
42. Bellmunt J, Theodore C, Demkov T et al (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27: 4454-4461.
43. Vishnu P, Mathew J, Tan WW (2011) Current therapeutic strategies for invasive and metastatic bladder cancer. Onco Targets Ther 4: 97-113.
44. Levi F, Ferlay J, Galeone C et al (2008) The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int 101: 949-958.
45. Yang JC, Sherry RM, Steinberg SM et al (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21: 3127-3132.
46. McDermott DF, Regan MM, Clark JI et al (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23: 133-141.
47. Medical Research Council Renal Cancer Collaborators (1999) Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353: 14-17.
48. Siebels M, Rohrmann K, Oberneder R et al (2011) A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 29: 121-126.
49. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124.
50. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134.
51. Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590.
52. Benedict A, Figlin RA, Sandstrom P et al (2011) Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU Int 108: 665-672.
53. Herrmann E, Marschner N, Grimm MO et al (2011) Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World J Urol 29: 361-366.
54. Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103-2111.
55. Escudier B, Bellmunt J, Negrier S et al (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28: 2144-2150.
56. Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28: 1061-1068.
57. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281.
58. Weikert S, Kempkensteffen C, Busch J et al (2011) Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors. World J Urol Apr 22 (Epub ahead of print).
59. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456.
60. Maclennan SJ, Maclennan SJ, Imamura M et al (2011) Urological cancer care pathways: development and use in the context of systematic reviews and clinical practice guidelines. World J Urol 29: 291-301.